Preoperative Radiomic Approach to Evaluate Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma Patients Using Contrast-Enhanced Computed Tomography

被引:72
作者
Liao, Haotian [1 ,4 ]
Zhang, Zhen [2 ]
Chen, Jie [2 ]
Liao, Mingheng [1 ,4 ]
Xu, Lin [1 ,4 ]
Wu, Zhenru [3 ]
Yuan, Kefei [1 ,4 ]
Song, Bin [2 ]
Zeng, Yong [1 ,4 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Liver Surg, Liver Transplantat Div, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Pathol, Lab Pathol, Chengdu, Sichuan, Peoples R China
[4] Sichuan Univ, West China Hosp, Lab Liver Surg, Chengdu, Sichuan, Peoples R China
关键词
IMMUNE CELLS; BLOCKADE; SURVIVAL; PEMBROLIZUMAB; EXPRESSION; IMAGES;
D O I
10.1245/s10434-019-07815-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. To help identify potential hepatocellular carcinoma (HCC) candidates for immunotherapies, we aimed to develop and validate a radiomics-based biomarker (Rad score) to predict the infiltration of tumor-infiltrating CD8(+) T cells in HCC patients, and to evaluate the correlation of Rad score with tumor immune characteristics. Methods. Overall, 142 HCC patients (n = 100 and n = 42 in the training and validation sets, respectively) were subjected to radiomic feature extraction. Imaging features and immunochemistry data of patients in the training set were subjected to elastic-net regularized regression analysis to predict the level of CD8(+) T cell infiltration. Results. A Rad score for CD8(+) T-cell infiltration, which contained seven variables, was developed and was validated in the validation set (area under the curve [AUC]: training set 0.751, 95% confidence interval [CI] 0.656-0.846; validation set 0.705, 95% CI 0.547-0.863). The decision curve indicated the clinical usefulness of the Rad score. A higher Rad score correlated with superior overall and disease-free survival outcomes (p = 0.012 and 0.0088, respectively). Using the pathological slides, we found that the Rad score positively correlated with the percentage of tumor-infiltrating lymphocytes (TILs; Spearman rho = 0.51, p < 0.0001). Moreover, the Rad score could also discriminate inflamed tumors from immune-desert and immune-excluded tumors (Kruskal-Wallis, p < 0.0001), and higher Rad scores could be found in patients with positive programmed cell death ligand 1 expression in tumor/immune cells, as well as those with positive programmed cell death protein 1 expression. Conclusion. The newly developed Rad score was a powerful predictor of CD8(+) T-cell infiltration, which could be useful in identifying potential HCC patients who can benefit from immunotherapies when validated in large-scale prospective cohorts.
引用
收藏
页码:4537 / 4547
页数:11
相关论文
共 40 条
[1]   Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach [J].
Aerts, Hugo J. W. L. ;
Velazquez, Emmanuel Rios ;
Leijenaar, Ralph T. H. ;
Parmar, Chintan ;
Grossmann, Patrick ;
Cavalho, Sara ;
Bussink, Johan ;
Monshouwer, Rene ;
Haibe-Kains, Benjamin ;
Rietveld, Derek ;
Hoebers, Frank ;
Rietbergen, Michelle M. ;
Leemans, C. Rene ;
Dekker, Andre ;
Quackenbush, John ;
Gillies, Robert J. ;
Lambin, Philippe .
NATURE COMMUNICATIONS, 2014, 5
[2]  
[Anonymous], 2020, Radiology
[3]   Tumor-infiltrating, interleukin-33-producing effector-memory CD8+ T cells in resected hepatocellular carcinoma prolong patient survival [J].
Brunner, Stefan M. ;
Rubner, Christoph ;
Kesselring, Rebecca ;
Martin, Maria ;
Griesshammer, Eva ;
Ruemmele, Petra ;
Stempfl, Thomas ;
Teufel, Andreas ;
Schlitt, Hans J. ;
Fichtner-Feigl, Stefan .
HEPATOLOGY, 2015, 61 (06) :1957-1967
[4]   Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma: Relationship With Clinical and Pathological Features [J].
Calderaro, Julien ;
Rousseau, Benoit ;
Amaddeo, Giuliana ;
Mercey, Marion ;
Charpy, Cecile ;
Costentin, Charlotte ;
Luciani, Alain ;
Zafrani, Elie-Serge ;
Laurent, Alexis ;
Azoulay, Daniel ;
Lafdil, Fouad ;
Pawlotsky, Jean-Michel .
HEPATOLOGY, 2016, 64 (06) :2038-2046
[5]   Elements of cancer immunity and the cancer-immune set point [J].
Chen, Daniel S. ;
Mellman, Ira .
NATURE, 2017, 541 (7637) :321-330
[6]   Cancer Statistics in China, 2015 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Baade, Peter D. ;
Zhang, Siwei ;
Zeng, Hongmei ;
Bray, Freddie ;
Jemal, Ahmedin ;
Yu, Xue Qin ;
He, Jie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132
[7]   Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy [J].
Denkert, Carsten ;
von Minckwitz, Gunter ;
Darb-Esfahani, Silvia ;
Lederer, Bianca ;
Heppner, Barbara I. ;
Weber, Karsten E. ;
Budczies, Jan ;
Huober, Jens ;
Klauschen, Frederick ;
Furlanetto, Jenny ;
Schmitt, Wolfgang D. ;
Blohmer, Jens-Uwe ;
Karn, Thomas ;
Pfitzner, Berit M. ;
Kuemmel, Sherko ;
Engels, Knut ;
Schneeweiss, Andreas ;
Hartmann, Arndt ;
Noske, Aurelia ;
Fasching, Peter A. ;
Jackisch, Christian ;
van Mackelenbergh, Marion ;
Sinn, Peter ;
Schem, Christian ;
Hanusch, Claus ;
Untch, Michael ;
Loibl, Sibylle .
LANCET ONCOLOGY, 2018, 19 (01) :40-50
[8]   A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma [J].
Dhir, Mashaal ;
Melin, Alyson A. ;
Douaiher, Jeffrey ;
Lin, Chi ;
Zhen, Weining ;
Hussain, Shahid M. ;
Geschwind, Jean-Francois H. ;
Doyle, Maria B. Majella ;
Abou-Alfa, Ghassan K. ;
Are, Chandrakanth .
ANNALS OF SURGERY, 2016, 263 (06) :1112-1125
[9]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502
[10]   Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma [J].
Erdag, Gulsun ;
Schaefer, Jochen T. ;
Smolkin, Mark E. ;
Deacon, Donna H. ;
Shea, Sofia M. ;
Dengel, Lynn T. ;
Patterson, James W. ;
Slingluff, Craig L., Jr. .
CANCER RESEARCH, 2012, 72 (05) :1070-1080